Pituitary carcinoma: a clinicopathologic study of 15 cases
- PMID: 9024719
- DOI: 10.1002/(sici)1097-0142(19970215)79:4<804::aid-cncr18>3.0.co;2-3
Pituitary carcinoma: a clinicopathologic study of 15 cases
Abstract
Background: Pituitary carcinomas are rare adenohypophysial neoplasms, the definition, diagnosis, therapy, and prognosis of which are controversial.
Methods: Pituitary carcinomas were defined as primary adenohypophysial neoplasms with documented craniospinal and/or systemic metastases. The authors report a clinicopathologic study of 15 examples examined by light microscopy, immunohistochemistry, and image analysis. Both proliferative activity and p53 tumor suppressor gene expression were studied.
Results: The study group consisted of 15 patients, including 8 males and 7 females ranging in age from 34-71 years (mean, 56 years). Of these patients, seven had adrenocorticotropic hormone (ACTH)-producing tumors (four in the context of Nelson's syndrome), seven had prolactin-producing tumors, and one had a nonfunctioning tumor. No evidence of diabetes insipidus was seen in any case. Fourteen tumors were initially considered macroadenomas. Of the ten cases for whom tumor extent was known, all had invasive tumors. The interval from the initial diagnosis of adenoma to that of carcinoma ranged from 0.3 to 18.0 years (mean, 6.6 years; median, 5.0 years); the longest mean interval (15.3 years) occurred for patients with Nelson's syndrome. The latency was twice as long for ACTH-producing tumors as for prolactin (PRL) cell tumors (9.5 vs. 4.7 years). All carcinomas showed a greater tendency toward systemic metastasis than craniospinal metastasis; the rate of systemic metastasis was 71% for PRL cell tumors and 57% for ACTH-producing tumors. Thirteen percent of tumors showed both patterns of metastasis. Fully 50% of primary tumors and the majority of metastases showed nuclear pleomorphism and/or hyperchromasia. The mean mitotic, MIB-1, and proliferating cell nuclear antigen indices for primary tumors and metastases were as follows: 2/10 high-power field (hpf), 2.6% and 11%, respectively; 6/10 hpf, 7.8% and 16%, respectively. Staining for p53 protein was noted in 57% of primary tumors and 88% of metastatic tumors; a relative increase in p53 expression in metastases was noted in 83%. All but one of the primary and metastatic tumors were aneuploid. The most common treatments were radiation therapy and, for PRL cell carcinomas, dopamine agonist administration. Both treatments provided only palliation. Eighty percent of the patients died of metastatic disease 7 days to 8 years after the diagnosis of carcinoma; of these, 66% died within 1 year. At last follow-up, 20% of patients were alive with metastases 9-18 months after diagnosis.
Conclusions: Nearly all pituitary carcinomas present as functioning, microscopically atypical or mitotically active, invasive macroadenomas. By definition, after an interval related to their immunotype, all metastasize. The tumors show a greater tendency toward systemic metastasis than craniospinal metastasis and are associated with poor prognosis. Radiation and dopamine agonist therapy generally provide only palliation. Proliferation indices and p53 expression tend to be higher in metastases than in primary tumors. The current definition of pituitary carcinoma requires the demonstration of metastasis; however, high mitotic and MIB-1 labeling indices as well as p53 immunoreactivity suggest the diagnosis and appear to be of prognostic significance. A redefinition of aggressive pituitary tumors is proposed--one that facilitates the recognition of tumors prone to metastasis.
Similar articles
-
[Pituitary carcinoma. Anatomic and clinical features of cases reported in literature].Neurochirurgie. 2007 Aug;53(4):284-8. doi: 10.1016/j.neuchi.2007.01.001. Neurochirurgie. 2007. PMID: 17524431 Review. French.
-
Pathobiology of pituitary adenomas and carcinomas.Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53. doi: 10.1227/01.NEU.0000223437.51435.6E. Neurosurgery. 2006. PMID: 16883174
-
Pituitary carcinoma: a review of the literature.Neurosurg Focus. 2004 Apr 15;16(4):E7. doi: 10.3171/foc.2004.16.4.8. Neurosurg Focus. 2004. PMID: 15191336 Review.
-
Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases.J Neurosurg. 2002 Feb;96(2):352-60. doi: 10.3171/jns.2002.96.2.0352. J Neurosurg. 2002. PMID: 11838811
-
Pituitary carcinoma: an ultrastructural study of eleven cases.Ultrastruct Pathol. 2001 May-Jun;25(3):227-42. doi: 10.1080/019131201300343865. Ultrastruct Pathol. 2001. PMID: 11465479
Cited by
-
A Rare Prolactin-secreting Pituitary Carcinoma With Epidural and Thecal Metastases.JCEM Case Rep. 2024 Apr 24;2(5):luae047. doi: 10.1210/jcemcr/luae047. eCollection 2024 May. JCEM Case Rep. 2024. PMID: 38660486 Free PMC article.
-
Case report: Identification of potential prognosis-related LAG3 overexpression and DICER1 mutation in pituitary carcinoma: two cases.Front Neurosci. 2023 Oct 12;17:1191596. doi: 10.3389/fnins.2023.1191596. eCollection 2023. Front Neurosci. 2023. PMID: 37901430 Free PMC article.
-
Metastatic pituitary tumors: an institutional case series.Pituitary. 2023 Oct;26(5):561-572. doi: 10.1007/s11102-023-01341-4. Epub 2023 Jul 31. Pituitary. 2023. PMID: 37523025
-
The Party Wall: Redefining the Indications of Transcranial Approaches for Giant Pituitary Adenomas in Endoscopic Era.Cancers (Basel). 2023 Apr 10;15(8):2235. doi: 10.3390/cancers15082235. Cancers (Basel). 2023. PMID: 37190164 Free PMC article. Review.
-
Approach to the Patient With Prolactinoma.J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-2423. doi: 10.1210/clinem/dgad174. J Clin Endocrinol Metab. 2023. PMID: 36974474 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous